-
May 21, 2021
Tchaikapharma Highquality Medicines, a flagship company on the Bulgarian pharma market, started trading shares on the Bulgarian Stock Exchange (BSE) on 21 May 2015. On today’s date exactly 6 years ago, the initial offering price per share was BGN 3.59, and on 21 May 2021 – BGN 14.10. This represents a growth of 292.757% over the entire period and a CAGR of 25.6%. This impressive increase does not take into account any dividend received in the form of new shares over the years, which further enhances the return on investment (ROI).
After its market cap surpassed BGN 1 billion at the end of June 2020, Tchaikapharma remains the most expensive company on the BSE with a capitalization of BGN 1,159,020,000.
At the beginning of this year, the company changed its stock code – it is now THQM as of 15 February 2021.
-
February 23, 2021
SOFIA (Bulgaria), February 23 (SeeNews) – Bulgarian drug maker Tchaikapharma High Quality Medicines [BUL:7TH] said that its shareholders have approved its plan to borrow up to 14 million euro ($17.2 million) in order to finance the construction of a new production plant just outside Sofia.
The proposal was supported by all shareholders present at the meeting, representing 99.88% of the total voting rights, Tchaikapharma said in a stock exchange filing on Monday.
The loan, to be provided by local lender United Bulgarian Bank (UBB), will have an interest rate of between 2% and 3%. The eight-year loan agreement will have a three-year grace period.
Read the original article here.
-
February 3, 2021
At the beginning of February, one share of the company costs BGN 13.80, which means that the market capitalization of the pharmaceutical equals 1.13 billion leva.
Read the full article here in Bulgarian.
-
December 22, 2020
We say goodbye to a historic year, marked by unprecedented difficulties in medical, economical, political and of course, in pure human terms. With hard work and effective oganization, in this difficult time, we could assure that the Bulgarian population had access to reliable and affordable medical prevention and early COVID-19 treatment with hydroxychloroquine. At the same time, by developing, manufacturing and registering it in Bulgaria, we have restored access to thousands of patients suffering from lupus and rheumatoid arthritis to this essential medicine. Tchaikapharma is the only Bulgarian manufacturer of injectable antibiotics, which are vitally important for the hospitals in the country. Obviously, these achievements did not go unnoticed on the Bulgarian stock exchange.
Read the original article here.
-
October 5, 2020
Patients with rheumatic disease are less likely to suffer from coronavirus, especially those taking hydroxychloroquine. That is why their therapy should not be interrupted during the pandemic, says rheumatologist Prof. Rasho Rashkov and clarifies that he and his colleagues have many years of experience in the treatment with hydroxychloroquine, as well as treatment of some of the complications caused by the infection.
The full article is available here in Bulgarian.